Zhang Hui, Wang Jing-Yan, Lv Jian-Hua, Hu Hai-Bo, Xie Rui-Gang, Jin Qi, Pang Kun-Jing, Xu Liang, Xu Zhong-Ying, Zhang Ge-Jun, Pan Xiang-Bin
Department of Radiology, Zhengzhou University People's Hospital, Central China Fuwai Hospital, Heart Center of Henan Provincial People's Hospital, Zhengzhou, China.
Department of Cardiology, Yuncheng Central Hospital, Yuncheng, China.
Front Cardiovasc Med. 2021 Feb 26;8:589947. doi: 10.3389/fcvm.2021.589947. eCollection 2021.
Transcatheter closure of paravalvular leak (PVL) has evolved into an alternative to surgery in high-risk patients. In this study, we introduce a new access for transcatheter closure of PVL and seek to evaluate the feasibility and safety of this access. We retrospectively analyzed patients undergoing transbrachial access for transcatheter mitral or aortic PVL closure (August 2017-November 2019) at our hospital. All patients underwent puncture of the brachial artery under local anesthesia. The study population included 11 patients, with an average age of 55.91 ± 14.82 years. Ten out of 11 patients were successfully implanted with devices the brachial artery approach, and one patient was converted to the transseptal approach. The technical success rate of transbrachial access was 90.9%. Mean NYHA functional class improved from 3.1 ± 0.5 before the procedure to 1.9 ± 0.5 after PVL closure. Severe paravalvular regurgitation (PVR) in five patients and moderate PVR in six patients prior to the procedure were significantly reduced to mild in four patients and none in seven patients after the procedure. Complications included one case of pseudoaneurysm and one case of moderate hemolysis aggravation after closure. One patient had an unknown cause of sudden death within 24 h after the procedure. The half-year mortality rate during follow-up was 9.1% (1/11). Transbrachial access for transcatheter closure of PVL may be a feasible and safe treatment and should include well-selected patients. It has several potential advantages of simplifying the procedure process and reducing postprocedural bed rest time.
经导管封堵瓣周漏(PVL)已成为高危患者手术治疗的替代方法。在本研究中,我们介绍了一种用于经导管封堵PVL的新入路,并试图评估该入路的可行性和安全性。我们回顾性分析了我院2017年8月至2019年11月期间接受经肱动脉途径经导管二尖瓣或主动脉瓣PVL封堵术的患者。所有患者均在局部麻醉下进行肱动脉穿刺。研究人群包括11例患者,平均年龄为55.91±14.82岁。11例患者中有10例通过肱动脉途径成功植入封堵装置,1例患者转为经房间隔途径。经肱动脉入路的技术成功率为90.9%。纽约心脏协会(NYHA)心功能分级平均从术前的3.1±0.5改善至PVL封堵术后的1.9±0.5。术前5例严重瓣周反流(PVR)患者和6例中度PVR患者在术后显著减轻至4例轻度和7例无反流。并发症包括1例假性动脉瘤和封堵术后1例中度溶血加重。1例患者在术后24小时内原因不明突然死亡。随访期间半年死亡率为9.1%(1/11)。经肱动脉途径经导管封堵PVL可能是一种可行且安全的治疗方法,应选择合适的患者。它具有简化手术过程和减少术后卧床时间等几个潜在优势。